ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1150

A Comparative Study of Cryofibrinogenemia Before and After COVID-19 Era

Carmen Lasa1, Maria Enriqueta Peiró2, Juan Irure-Ventura2, Amparo Sánchez2, Adrian Martin-Gutierrez2, carmen secada2, monica renuncio garcia2, Marcos Lopez-Hoyos3 and Ricardo Blanco4, 1Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: skin, Stroke

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Cryofibrinogenemia (CF) is an under-recognized syndrome due to the lack of definitive criteria and the rarity of disease. CF may be primary (essential) or secondary to autoimmune, neoplastic or infections conditions. Skin manifestations, mainly ulceration, are the most common and may be a pseudovasculitic syndrome. During COVID-19 era the number of cases with skin lesions get increased. Further studies are needed to characterize this association between CF and SARS-CoV-2.

Methods: Observational single-center study in northern Spain University Hospital of 134 patients with at least one positive cryofibrinogen determination, between January 2017 and March 2020 (preCOVID era) and March 2020 and December 2022 (COVID era). CF diagnosis was confirmed accordingly to reported criteria.Clinical conditions, laboratory parameters, including immunological and serological analysis were collected from all patients. Blood was collected in citrated tubes for cryofibrinogen detection. Stadistical analysis was performed using SPSS software. Quantitative variables were expressed as mean±SD. Qualitative variables were compared using the Fisher’s exact test or the chi-squared test, according to sample size. Quantitative variables were compared using the student’s t.

Results: CF was confirmed in 19/134 (14.2%) patients with at least one positive cryofibrinogen test determination (preCOVID-19 era=5; COVID-19 era=14). Patients of COVID-19 era were more frequently male (64.3% vs 40%) and younger (43.6 vs 60.6). Main features are shown in Table 1. We observed a change in the distribution cases. In preCOVID-19 era most of cases were essential CF (60%) and in COVID-19 era most of them were secondary ones (64.3%). The 33.3% of secondary CF were mainly due to COVID-19. Cutaneous manifestations were similar in both subgroups, especially as purpuric macules (perniosis-like) in acral distributions and no significant association was noted between both eras. Antiaggregant drugs and corticosteroids were used more frequently in preCOVID-19 era. The comparative incidence after and before COVID-19 is shown in Figure 1. From patients with positive cryofibrinogen test, a greater proportion in preCOVID-19 had a CF.

Conclusion: CF is a rare disorder with a low prevalence. This study showed the change in the trend of CF subtypes, probably due to the influence of the COVID-19 infection. In COVID-19 era the number of positive cryofibrinogen test had envolved due to SARS-CoV2 infection, CF cases were not increased. Clinical expression of the disease has not changed in both groups.

Supporting image 1

Supporting image 2


Disclosures: C. Lasa: None; M. Peiró: None; J. Irure-Ventura: None; A. Sánchez: None; A. Martin-Gutierrez: None; c. secada: None; m. renuncio garcia: None; M. Lopez-Hoyos: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

Lasa C, Peiró M, Irure-Ventura J, Sánchez A, Martin-Gutierrez A, secada c, renuncio garcia m, Lopez-Hoyos M, Blanco R. A Comparative Study of Cryofibrinogenemia Before and After COVID-19 Era [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-comparative-study-of-cryofibrinogenemia-before-and-after-covid-19-era/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-comparative-study-of-cryofibrinogenemia-before-and-after-covid-19-era/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology